Filtered By:
Condition: Diabetes
Education: Learning

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 345 results found since Jan 2013.

Severe paraneoplastic hypoglycemia secondary to a gastrointestinal stromal tumour masquerading as a stroke.
We report the case of a 70-year-old previously healthy female who presented acutely to the Accident and Emergency department with left-sided vasomotor symptoms including reduced muscle tone, weakness upon walking and slurred speech. Physical examination confirmed hemiparesis with VIIth nerve palsy and profound hepatomegaly. A random glucose was low at 1.7 mmol/l, which upon correction resolved her symptoms. In hindsight, the patient recalled having had similar episodes periodically over the past 3 months to which she did not give much attention. While hospitalized, she continued having episodes of symptomatic hypoglycaem...
Source: Diabetes Metab - November 7, 2015 Category: Endocrinology Authors: Dimitriadis GK, Gopalakrishnan K, Rao R, Grammatopoulos DK, Randeva HS, Weickert MO, Murthy N Tags: Endocrinol Diabetes Metab Case Rep Source Type: research

Deep learning fully convolution network for lumen characterization in diabetic patients using carotid ultrasound: a tool for stroke risk
AbstractManual ultrasound (US)-based methods are adapted for lumen diameter (LD) measurement to estimate the risk of stroke but they are tedious, error prone, and subjective causing variability. We propose an automated deep learning (DL)-based system for lumen detection. The system consists of a combination of two DL systems: encoder and decoder for lumen segmentation. The encoder employs a 13-layer convolution neural network model (CNN) for rich feature extraction. The decoder employs three up-sample layers of fully convolution network (FCN) for lumen segmentation. Three sets of manual tracings were used during the traini...
Source: Medical and Biological Engineering and Computing - January 26, 2019 Category: Biomedical Engineering Source Type: research

AHA News: After Diabetes, Stroke and Heart Attack, She ' s Learning to ' Fight Smart '
Title: AHA News: After Diabetes, Stroke and Heart Attack, She ' s Learning to ' Fight Smart 'Category: Health NewsCreated: 5/21/2020 12:00:00 AMLast Editorial Review: 5/22/2020 12:00:00 AM
Source: MedicineNet Heart General - May 22, 2020 Category: Cardiology Source Type: news

Risk of Chronic Conditions Found Higher Among Certain Groups With Depression, Anxiety
Women aged 20 to 60 with depression or anxiety were more likely to develop multiple chronic conditions over time compared with similarly aged women without depression or anxiety, according to areport published this week in JAMA Network Open. Women with comorbid anxiety and depression had an even greater risk of developing chronic conditions.Similarly, men with depression and/or anxiety at age 20 were more likely than those without depression or anxiety to develop chronic conditions.“Our findings support the need for managing comorbid depression and anxiety, which may help lower the risk of premature mortality associated ...
Source: Psychiatr News - May 5, 2022 Category: Psychiatry Tags: anxiety asthma cancer chronic conditions coronary artery disease depression diabetes hypertension JAMA Network Open men risk stroke women Source Type: research

Act F.A.S.T. and Save a Life!
Yes, I'm getting older! My knees hurt for no reason at times and my joints pop and crack like an old house settling. Yet I continue to push through by working out regularly, eating healthy, and hoping to slow down Father Time and ignore my athletic mortality. Many of my physician colleagues admit to neglecting their health due to the busy lives they lead, but I try my best to practice what I preach. Stressing the importance of healthy eating, being physically active, taking medication as prescribed and regular follow ups with a physician is more than just a reflex recommendation to my patients. It is an integral part of my...
Source: Healthy Living - The Huffington Post - May 7, 2015 Category: Consumer Health News Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Oversleeping: The Effects and Health Risks of Sleeping Too Much
This article originally appeared on the Amerisleep blog. Rosie Osmun is the Creative Content Manager at Amerisleep, a progressive memory foam mattress brand focused on eco-friendly sleep solutions. Rosie writes more posts on the Amerisleep blog about the science of sleep, eco-friendly living, leading a healthy lifestyle and more. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.
Source: Healthy Living - The Huffington Post - January 29, 2016 Category: Consumer Health News Source Type: news

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit using...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Modifiable Lifestyle Factors and Cognitive Function in Older People: A Cross-Sectional Observational Study
Conclusions: Lifestyle factors, such as physical activity, sleep, and social activity appear to be associated with cognitive function among older people. Physical activity and appropriate durations of sleep and conversation are important for cognitive function. Introduction Dementia is a major public health issue worldwide, with a serious burden for patients, caregivers, and society, as well as substantial economic impacts (1). Although the prevalence of late-life cognitive impairment and dementia are expected to increase in future, effective disease-modifying treatments are currently unavailable. Therefore, unders...
Source: Frontiers in Neurology - April 23, 2019 Category: Neurology Source Type: research

Knockdown of NRSF Alleviates Ischemic Brain Injury and Microvasculature Defects in Diabetic MCAO Mice
Diabetes is one of the well-established risk factors of stroke and is associated with a poor outcome in patients with stroke. Previous studies have shown that the expression of neuron restrictive silencer factor (NRSF) is elevated in diabetes as well as ischemic stroke. However, the role of NRSF in regulating an outcome of diabetic ischemic stroke has not been completely understood. Here, we hypothesized that diabetes-induced NRSF elevation can aggravate brain injury and cognition impairment in ischemic stroke. The diabetic ischemic stroke mice model was established by 8 weeks of high-fat-diet feeding and 5 days of strepto...
Source: Frontiers in Neurology - May 13, 2022 Category: Neurology Source Type: research

Modern machine-learning can support diagnostic differentiation of central and peripheral acute vestibular disorders
ConclusionsEstablished clinical scores (such as HINTS) provide a valuable baseline assessment for stroke detection in acute vestibular syndromes. In addition, machine-learning methods may have the potential to increase sensitivity and selectivity in the establishment of a correct diagnosis.
Source: Journal of Neurology - June 10, 2020 Category: Neurology Source Type: research